Vimta Labs Limited · NSE:VIMTALABS
Vimta Labs — Q3 FY2023 Earnings Presentation
37 slides from Vimta Labs's earnings presentation, February 2023
Slide 1: Investor Presentation
Slide 2: Established in 1984, VIMTA is one of India's most renowned CRO companies
Established in 1984, VIMTA is one of India’s most renowned companies for contract research and testing, recognized for its high quality, cutting edge technology enabled wide spectrum, reliable services and vast experience. The company’s broad capabilities span across biologics, small molecules, agro
Slide 3: Our Vision and Core Values
Our Vision To be an Indian organization with a global perspective that has created an integrated, quality-driven, customer- sensitive, contract research and testing center that is the most comprehensive of its kind across the globe. Our Core Values Integrity of service through honesty, responsibilit
Slide 4: Our Belief & Commitment
Our Belief & Commitment We believe our work impacts the wellbeing of HONESTY millions of people across the globe. Our responsibility is to the end consumers and patients who INTEGRITY use our services and the products we help discover, develop or test for quality. In protecting the interests for the
Slide 5: Culture and Corner Stones
Culture and Corner Stones QUALITY PEOPLE We Prioritize: • Long term organizational reputation & sustainability vs short term interests • Adapting to customer needs and latest technologies to deliver value • Our people, and the promises we make to our customers INNOVATION TECHNOLOGY Driven by Quality
Slide 6: Geographical Presence
Geographical Presence Headquartered in Hyderabad, VIMTA has 20 laboratories across India, with a total laboratory space of over 400,000 sq. ft. Food Hyderabad (Head Quarters) Clinical Diagnostics Ahmedabad Food Noida Chennai Mumbai (NFL) Delhi Clinical Diagnostics Pune Noida Bengaluru Varanasi Pharm
Slide 7: Key Management Team
Harita Vasireddi Managing Director Harriman Vungal Executive Director - Sreenivas Neerukonda Operations Executive Director Key Management Team Suresh Kumar Narahai Naidu D.R. President Chief Financial Officer Driven by Quality. Inspired by Science. 7
Slide 8: Our Journey over the years
Our Journey over the years Infrastructure People Investment Capabilities Revenues Pharma & Biopharma: Discovery & 2022 400,000+ ft2 1300+ 337 M development services; Food; 2783 M Environment; Clinical Diagnostics; Electronics 2015 Analytical – Pharma, Biopharma & 400,000+ ft2 1000+ 580 M Food; Clini
Slide 9: Service Profile
Service Profile Pharma Clinical Analytical Preclinical Research Food Clinical Electronics & Environment Diagnostics Electricals Driven by Quality. Inspired by Science. 9
Slide 10: Integrated Partner for Drug Discovery & Development
INTEGRATED PARTNER FOR DRUG DISCOVERY & DEVELOPMENT Drug life cycle management, development and discovery support services in the areas of preclinical research, clinical research, central lab and cGMP analytical services for pharmaceutical and biopharmaceutical companies. ANALYTICAL SERVICES FOR DRU
Slide 11: ...Integrated Partner for Drug Discovery & Development: Clinical Research
…INTEGRATED PARTNER FOR DRUG DISCOVERY & DEVELOPMENT CLINICAL RESEARCH SERVICES With experience and expertise gained from over 2000 clinical studies, studies and reinforced with an impressive track record of successful global regulatory audits from national and international regulatory authorities (
Slide 12: ...Integrated Partner for Drug Discovery & Development: Preclinical
…INTEGRATED PARTNER FOR DRUG DISCOVERY & DEVELOPMENT PRECLINICAL SERVICES Our test facilities are Good Laboratory Practices (GLP) - certified by NGCMA, NGCMA and AAALAC accredited. accredited Our wide gamut of preclinical services to pharmaceutical, biotech, medical device and chemical companies inc
Slide 13: Clinical Diagnostics
CLINICAL DIAGNOSTICS We have a strong brand equity and a pan India presence offering both routine and specialized diagnostic services. We have seven well equipped branch laboratories and two regional reference laboratories operated by a proficient team of doctors, technicians and business profession
Slide 14: Food & Agriculture Services
FOOD & AGRICULTURE SERVICES We offer routine as well as specialized testing services for food and agriculture products to assist with R&D, regulatory compliance, trade and internal quality requirements. With eight state-of-the-art food testing laboratories across India, VIMTA is a ‘National Referral
Slide 15: Environment Testing & Consultancy
ENVIRONMENT TESTING & CONSULTANCY We have been providing Environment Impact Assessments and Environment Testing since inception and have gained substantial expertise. We provide our services to various industries such as power, infrastructure, steel, cement, oil & gas, mining, pharmaceutical, food,
Slide 16: Electronics & Electrical Testing
ELECTRONICS & ELECTRICAL TESTING Newly launched EMI / EMC services cater to IT, automotive, aviation & defense, medical devices, telecom, home appliance / consumer electronics and allied industries. Services • EMI / EMC TESTING Radiated Conducted • Environmental testing • Mechanical & electrical
Slide 17: Accreditations, Approvals, and Regulatory Inspections
Accreditations, Approvals, and Regulatory Inspections C e rt i fi ed A p p roved A c cred it ed A p p roved E I C A p p ro ved R e g is t ered A c cred it ed I n s p ect ed C e rt i fi ed P r e - Qu al if ied A p p roved DCA OECD India GLP A p p roved A p p roved A p p roved A p p roved A p p roved
Slide 18: Our Strengths
Our Strengths Long & successful regulatory track record – Long term partnerships cGMP, GLP, GCP with customers Unparalleled lab infrastructure in the country. Gold LEED Multi-disciplinary, certified Vivarium knowledgeable, skilled and trained manpower Wide range of current technologies with expandab
Slide 19: Our Key Growth Drivers & Strategies
Our Key Growth Drivers & Strategies We aspire to reach revenues of >Rs.500 cr by 2025. 2025 The growth will be propelled by all our core services through multi- multi-pronged strategic focus. Growth momentum Capacity expansions Operational excellence Good corporate in markets governance Se
Slide 20: Factors driving industry growth
Factors driving industry growth • Increasing demand for new drug innovations, growth in biologics and vaccine products development, and increasing regulations in pharma and biotech industry • Growing international food regulations, evolving Indian food safety regulations, growing world population, a
Slide 21: Markets
Markets (USD bn) bn) 20 14.6 10 12.3 7.6 5.4 0.6 0.10 0.33 0.27 0.39 0.05 2022 2022 | 2030 2022 2022 | 2030 2022 2022 | 2030 2022 2022 | 2026 2022 2022 | 2026 2021 2021 | 2028 Pharmaceutical and Preclinical Food Testing Clinical Diagnostics Environment testing Electronics testing Biopharmaceutical C
Slide 22: Our Position in the CRTO Landscape
Our Position in the CRTO Landscape Pharma Analytical & Food Testing Preclinical • #11 in India • #1 in India • Customers – 90% of India • Customers – 70% of India top 20 top 10 • 30% revenues from overseas Clinical Research Environment • Among the most • Among top 5 in India reputed CROs in India •
Slide 23: Pharma Analytical
FY20, FY21 – Operational Highlights: PHARMA ANALYTICAL • Successful USFDA remote record review • EU approval for a customer’s medical device (extractable and leachable study) • Single method developed and validated for estimation of 12 nitrosamine compounds in a drug product • USFDA approval for cus
Slide 24: Food Division
FY20, FY21 – Operational Highlights: FOOD DIVISION • Won a 25 years PPP contract to setup & operate National Food Lab (JNPT) FSSAI • Launched ETO testing for guargum and botanicals • Obtained AFNOR approval for VIDAS method, launched Salmenolla testing in betel leaves • Developed & validated 44 meth
Slide 25: Preclinical
FY20, FY21 – Operational Highlights: PRECLINICAL • USFDA accepted non-clinical data generated for a customer in Malaysia for Standardized Extract Kacip Fatimah and allowed as a New Dietary Ingredient. • New pharmacology animal models developed for oncology, pain & inflammation, and metabolic disorde
Slide 26: Clinical Research
FY20, FY21 – Operational Highlights: CLINICAL RESEARCH • Successful USFDA remote record review • Launched Inhalation BA / BE studies • Launched Gel Administration BA / BE studies on skin • Conducted studies on multiple formulations to support 505(b)(2) applications Driven by Quality. Inspired by Sci
Slide 27: Clinical Diagnostics
FY20, FY21 – Operational Highlights: CLINICAL DIAGNOSTICS • 1st Lab in Telangana State to be approved by ICMR for COVID-19 testing • Opened regional clinical reference labs in Delhi, Kolkata • Opened 6 COCOs (Company owned and company operated) patient service centers in Hyderabad (5) and Varanasi (
Slide 28: Environment
FY20, FY21 – Operational Highlights: ENVIRONMENT • New services launched / conducted: conducted o CEMS calibration studies; o SPOT Emission Monitoring in Cement & Power Sectors o Life cycle assessment studies for various industries o Bio-Accumulation Studies; o Ecological Damage Assessment studies;
Slide 29: Financial Performance
Financial Performance Driven by Quality. Inspired by Science. 29
Slide 30: Company Performance
Company Performance Total Revenue (INR Mn) Mn) Operating Margin (EBITDA) 27.7% 29.2% CAGR 15% 25.2% 25.4% 17.0% 18.3% 17.9% 15.8% 2,783 817 2,126 2,107 1,834 1,807 595 538 1,534 464 1,247 1,073 330 282 199 184 FY2015 FY2016 FY2017 FY2018 FY2019 FY2020 FY2021 FY2022 FY2015 FY2016 FY2017 FY2018 FY2019
Slide 31: Company Performance
Company Performance Profit After Tax Margin (Net Income) 14.8% Robust Sales growth at 15% CAGR between 2015 11.8% 10.1% and 2022 8.9% 6.9% 413 5.1% 4.7% 3.7% Significant Margin expansion at EBITDA level by about 1220 bps between 2015 and 2022 253 214 164 The Group Net Profit and EPS increased 8X tim
Slide 32: FY23 Highlights – Consolidated Performance
FY23 Highlights – Consolidated Performance • Quarterly total income at INR 785.1 Million and PBT at INR 140.8 RobustMillion Sales growth at 15% CAGR between 2015 and 2022 • Operating revenue for the qtr increased by 15.4% compared to same qtr last year. Significant Margin expansion at EBITDA level b
Slide 33: Profit & Loss Statement QoQ comparison
Profit & Loss Statement QoQ comparison Particulars Q3 FY23 Q2 FY23 Q3 FY22 Income Revenue from Operations 773.84 798.54 673.40 Other Income 11.24 7.62 7.14 Total Income 785.08 806.16 680.54 Expenses Material and Testing Costs 173.13 166.42 167.60 Cost of lab setup 14.92 0.97 14.37 Employee benefits
Slide 34: Profit & Loss Statement YTD comparison
Profit & Loss Statement YTD comparison Particulars Nine Months Ended Nine Months Ended Company Year Ended 31 December 2022 31 December 2021 31 March 2022 Income Revenue from Operations 2,363.70 2,041.91 2,782.79 Other Income 27.77 10.10 14.49 Total Income 2,391.47 2,052.01 2,797.28 Expenses Material
Slide 35: Shareholding Pattern
Shareholding Pattern Others Promoter & 62.75% Promoter Group 37.25% As on June 30, 2022 Driven by Quality. Inspired by Science. 35
Slide 36: Disclaimer
DISCLAIMER Certain statements in this Release concerning our future growth prospects are forward-looking statements, which are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those contemplated in such forward-looking statements.
Slide 37: Registered Office and Life Science Facility
g{tÇ~ lÉâ Registered Office Life Science Facility PLot Number 142, IDA Phase 2 #5, M N Park, Genome Valley Cherlapally, Hyderabad Shameeerpet, Hyderabad Telangana, India. 500101 Telangana, India. 500051